Retatrutide cuts apnea-hypopnea index in two Phase 3 sleep apnea trials

The wire

1. 01NEJM published TRIUMPH-1-OSA (243 participants) and TRIUMPH-2-OSA (448 participants), testing once-weekly retatrutide at 4, 9 and 12 mg in moderate-to-severe OSA with BMI of at least 27.
2. 02Placebo-adjusted AHI reductions reached 24.4 events per hour without diabetes and 15.1 with diabetes; weight loss ranged from 12.1% to 22.2% versus 4.8% to 5.6% on placebo.
3. 03Retatrutide remains investigational; the trials were nested in larger basket studies and used a hybrid-treatment estimand alongside intention-to-treat analyses.

From the source

Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea

The New England journal of medicine · 2026 Oct 21 · Grunstein RR, Somers VK, Azarbarzin A et al.